Oral oncolytics: How do they compare with existing standards of care?

The current insurance system is not efficiently equipped to handle the rapid expansion of oral oncolytics into the market, and the current insurance benefit design contributes significantly to access issues for patients. » More

Examining medication reconciliation from a perspective of safety

Recently published, systematically reviewed evidence suggests that there are certain characteristics of medication reconciliation processes that correlate favorably with clinically important patient safety outcomes. » More

Unauthorized prescribers bill Part D $5 million

Estimates of the cost of fraud in the Medicare system range broadly from $17 billion to $90 billion. However, there are no estimates of—or methods to detect—how much of the wasted money is attributable to old-fashioned human error rather than blatant crime. » More

Study finds that dapagliflozin demonstrates glycemic responses similar to other oral agents

Dapagliflozin produces larger reductions in HbA1c in individuals who have higher baseline levels, according to a study presented in June at the American Diabetes Association's 73rd Scientific Sessions, in Chicago. » More

Responsible use of drugs could save $200B annually

Delays in treatment and medication nonadherence are the major reasons behind avoidable costs in the healthcare system, according to an IMS study recently released. » More

Downloads

You are subscribed to the Formulary Issue Alert.

New molecular entity

An alternative to daily basal insulin treatment

FDA Pipeline

Adherence varies across market segments